ResultsIQ › Latest results › Cohance Lifesciences Limited
Cohance Lifesciences Limited Q2 FY27 results deck summary
NSE: COHANCE · BSE: 543064
Results deck of 7 Nov 2026, summarised by AI from the filing.
Cohance's Q2 FY27 revenue fell 14.2% YoY to ₹4,767 mn, but adjusted EBITDA margin recovered to 9.6% and H2 is guided to grow YoY.
Key takeaways
- H2 outlook Management expects H2FY27 revenue and EBITDA to grow YoY, with H2 stronger than H1.
- Margin rebound Adjusted EBITDA margin improved to 9.6% in Q2FY27 from 2.2% in Q1FY27.
- Sapala growth Nucleic acid business Sapala grew 33.6% YoY in Q2 on demand for nucleic-acid building blocks.
- CDMO decline Pharma CDMO revenue fell 27.4% YoY in Q2 and 32.7% in H1, weighing on overall revenue.
Cohance Lifesciences Limited Q2 FY27 results
As filed: Revenue ₹477 cr (−14% year on year), EBITDA ₹35.4 cr (−71% year on year), PAT ₹2.3 cr (−97% year on year), EBITDA margin 7.4% (−1,000 bps).
The Q2 FY27 score, against the company's own trend, is for premium members.
Earlier results and the share price after them
- Q1 FY27: Revenue ₹422 cr (−23% year on year), EBITDA ₹1.2 cr (−99% year on year), PAT −₹45.2 cr (−198% year on year), EBITDA margin 0.3% (−1,000 bps). Score 0 of 100, Below trend. EBITDA margin fell 1000 bps year on year. Not enough history for a trend yet: scored on growth alone. Revenue fell 32% from last quarter. Share price after the results: +6.3% in 30 days (Nifty 500: −2.0%).
- Q4 FY26: Revenue ₹619 cr (+54% year on year), EBITDA ₹98.7 cr (+33% year on year), PAT ₹8.3 cr (−30% year on year), EBITDA margin 15.9% (−247 bps). Score 55 of 100, In line with trend. EBITDA margin fell 247 bps year on year. Tax rate 58%. Not enough history for a trend yet: scored on growth alone. Profit fell 20% from last quarter. Share price after the results: −12.6% in 30 days (Nifty 500: −0.8%).
- Q3 FY26: Revenue ₹482 cr, EBITDA ₹103 cr, PAT ₹47.3 cr, EBITDA margin 21.3%. Not scored. No result for the same quarter last year. Share price after the results: −15.6% in 29 days (Nifty 500: −9.6%).
- H1 FY26: Revenue ₹981 cr, EBITDA ₹236 cr, PAT ₹147 cr, EBITDA margin 24.1%. Not scored. No result for the same half-year last year. Share price after the results: −22.3% in 30 days (Nifty 500: −0.5%).
- Q1 FY26: Revenue ₹484 cr, EBITDA ₹104 cr, PAT ₹53.0 cr, EBITDA margin 21.5%. Not scored. No result for the same quarter last year. Share price after the results: −0.6% in 30 days (Nifty 500: +2.2%).
- Q4 FY25: Revenue ₹330 cr, EBITDA ₹66.0 cr, PAT ₹44.0 cr, EBITDA margin 20.0%. Not scored. No result for the same quarter last year. Share price after the results: −14.9% in 30 days (Nifty 500: +3.7%).
Past price moves after results do not indicate future moves. Not a recommendation.
Cohance Lifesciences Limited earnings call, investor presentation and press release summaries
- Q2 FY27: Earnings call (6 Nov 2026), Results deck (7 Nov 2026)
- Q1 FY27: Earnings call (5 Aug 2026)
- Q4 FY26: Earnings call (12 May 2026)
- Q3 FY26: Earnings call (12 Feb 2026), Results deck (12 Feb 2026)
- Q2 FY26: Earnings call (12 Nov 2025), Results deck (12 Nov 2025)
- Q1 FY26: Earnings call (13 Aug 2025)
- Q4 FY25: Earnings call (28 May 2025), Results deck (28 May 2025)
- Other events: Special call (28 Oct 2025)
Figures from the company's filings with NSE and BSE. Not investment advice.